From Crystal Structure to Dissolution Enhancement: Cocrystal Engineering of Resmetirom to Address Its Solubility Challenge
{{output}}
Purpose: Resmetirom (RSM), the first FDA-approved drug for non‑cirrhotic steatohepatitis, suffers from poor aqueous solubility, limiting its oral bioavailability. This study aims to enhance the solubility of RSM through cocrysta... ...
